Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy

por Shiota, Masaki, Blas, Leandro, Eto, Masatoshi
Publicado 2022

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data

por Blas, Leandro, Shiota, Masaki, Eto, Masatoshi
Publicado 2022

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective

por Matsumoto, Takashi, Shiota, Masaki, Blas, Leandro, Eto, Masatoshi
Publicado 2022

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old

por Blas, Leandro, Onozawa, Mizuki, Shiota, Masaki, Hinotsu, Shiro, Sakamoto, Shinichi, Kitagawa, Yasuhide, Kawai, Taketo, Eto, Masatoshi, Kume, Haruki, Akaza, Hideyuki
Publicado 2021

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients

por Blas, Leandro, Shiota, Masaki, Nagakawa, Shohei, Tsukahara, Shigehiro, Matsumoto, Takashi, Lee, Ken, Monji, Keisuke, Kashiwagi, Eiji, Inokuchi, Junichi, Eto, Masatoshi
Publicado 2023

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

por Chikamatsu, Sotaro, Shiota, Masaki, Yamada, Shigetomo, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Publicado 2022

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

por Yamada, Shigetomo, Shiota, Masaki, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Publicado 2022

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors

por Shiota, Masaki, Akamatsu, Shusuke, Sekine, Yuya, Kimura, Hiroko, Narita, Shintaro, Fujimoto, Naohiro, Terada, Naoki, Blas, Leandro, Habuchi, Tomonori, Kamoto, Toshiyuki, Momozawa, Yukihide, Eto, Masatoshi
Publicado 2023

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy

por Blas, Leandro, Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, Eto, Masatoshi
Publicado 2022

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors

por Matsumoto, Takashi, Shiota, Masaki, Yamada, Shigetomo, Blas, Leandro, Naganuma, Hidekazu, Lee, Ken, Monji, Keisuke, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Publicado 2021

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology

por Secchiari, Florencia, Nuñez, Sol Yanel, Sierra, Jessica Mariel, Ziblat, Andrea, Regge, María Victoria, Raffo Iraolagoitia, Ximena Lucía, Rovegno, Agustín, Ameri, Carlos, Secin, Fernando Pablo, Richards, Nicolás, Ríos Pita, Hernando, Vitagliano, Gonzalo, Rico, Luis, Mieggi, Mauro, Frascheri, Florencia, Bonanno, Nicolás, Blas, Leandro, Trotta, Aldana, Friedrich, Adrián David, Fuertes, Mercedes Beatriz, Domaica, Carolina Inés, Zwirner, Norberto Walter
Publicado 2022